US Bancorp’s Greenwich LifeSciences GLSI Stock Holding History

US Bancorp’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15	Closed	-$360	–	4241
2026 Q1	$360	Buy	+15	New	+$391	﹤0.01%	4034

Other funds holding GLSI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

US Bancorp's GLSI Position: Q2 2026 in Review

US Bancorp sold out of Greenwich LifeSciences (GLSI) in Q2 2026, closing a stake of 15 shares — an estimated $360 sold.

US Bancorp first reported a position in GLSI in Q1 2026 and held it in 1 quarter. The position peaked at $360 in Q1 2026. 57 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

US Bancorp reported no remaining Greenwich LifeSciences position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 15 Greenwich LifeSciences shares in Q2 2026, an estimated $360.
US Bancorp first reported a position in Greenwich LifeSciences in Q1 2026 and held it in 1 quarter.
US Bancorp's Greenwich LifeSciences position peaked at $360 in Q1 2026.
57 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.